Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
6 days ago
6 days ago
touchEXPERT OPINIONS for touchIMMUNOLOGY
Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.
The expert
Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape
6 days ago
6 days ago
touchEXPERT OPINIONS for touchENDOCRINOLOGY
Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.
The expert
Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape
7 days ago
7 days ago
touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchONCOLOGY.com
7 days ago
7 days ago
touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchONCOLOGY.com
7 days ago
7 days ago
touchMDT for touchRESPIRATORY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchRESPIRATORY.com
7 days ago
7 days ago
touchMDT for touchRESPIRATORY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchRESPIRATORY.com
7 days ago
7 days ago
touchMDT for touchRESPIRATORY
What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.
The multidisciplinary team
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
7 days ago
7 days ago
touchMDT for touchRESPIRATORY
What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.
The multidisciplinary team
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
7 days ago
7 days ago
touchMDT for touchRESPIRATORY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/
7 days ago
7 days ago
touchMDT for touchONCOLOGY
What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.
The multidisciplinary team
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/